Roche Holdings Ltd ADR (RHHBY)

$53.34 +0.14 (0.26%)
Market Cap 338.91B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 17.32
Profit Margin 13.27%
Debt to Equity Ratio 1.00
Volume 2,467,700
Avg Vol 2,590,588
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 81%
Beta 0.44
Analysts Sell
Price Target $51.58

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 13 at 3:48 PM
$SLS $BMY $RHHBY Buyout Rumors swirling at the JPM Conference.
1 · Reply
Quantumup
Quantumup Jan. 13 at 1:18 PM
Piper Sandler⬆️ $ARWR's PT to $110 and reit'd at Overweight $IONS $WVE $RHHBY $REGN TEVA Piper Sandler said in its note: Arrowhead launched Redemplo for familial chylomicronemia syndrome (FCS), and we conservatively forecast sales of $8.4 million in FY:26 to grow to $41.6 million in FY:27. We are confident Arrowhead will report positive Phase III Redemplo data in severe hypertriglyceridemia in 3Q:26 with potential blockbuster label expansion in CY:27. Arrowhead reported impressive weight and fat loss data from the ongoing Phase I/II studies of ARO-INHBE and ARO-ALK7 with more data this year. Arrowhead initiated Phase I/ lla studies of ARO-DIMER-PA for ASCVD and ARO-MAPT for early Alzheimer's disease patients, both with initial data in 2026. Arrowhead issued $700 million in zero coupon convertible debt and raised $230 million in equity bringing pro forma cash to ~$2.09 billion and debt to ~$955 million. We reiterate our Overweight rating and are increasing our price target to $110 from $100.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 13 at 7:52 AM
$SLS $BMY $RHHBY SLS009 news is due, Expected to coincide with the JPM Conference - this week. - and the fact is after the Holidays, we are now at 77/78 events, Thanksgiving, Christmas and New Years post holiday events. Smart money knows this, and that P3 results will be announced before we know it, and when they do, $47 will be cheap. - only inch thick mile wide retail lemming tools - with the forethought of Gold FISH don't have clue what it means to actually INVEST... and get in Early and CHEAP -- like right now. https://www.reddit.com/r/sellasLifescience/s/469bdHkImx
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:52 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:52 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
2 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
Latest News on RHHBY
No data available.
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 13 at 3:48 PM
$SLS $BMY $RHHBY Buyout Rumors swirling at the JPM Conference.
1 · Reply
Quantumup
Quantumup Jan. 13 at 1:18 PM
Piper Sandler⬆️ $ARWR's PT to $110 and reit'd at Overweight $IONS $WVE $RHHBY $REGN TEVA Piper Sandler said in its note: Arrowhead launched Redemplo for familial chylomicronemia syndrome (FCS), and we conservatively forecast sales of $8.4 million in FY:26 to grow to $41.6 million in FY:27. We are confident Arrowhead will report positive Phase III Redemplo data in severe hypertriglyceridemia in 3Q:26 with potential blockbuster label expansion in CY:27. Arrowhead reported impressive weight and fat loss data from the ongoing Phase I/II studies of ARO-INHBE and ARO-ALK7 with more data this year. Arrowhead initiated Phase I/ lla studies of ARO-DIMER-PA for ASCVD and ARO-MAPT for early Alzheimer's disease patients, both with initial data in 2026. Arrowhead issued $700 million in zero coupon convertible debt and raised $230 million in equity bringing pro forma cash to ~$2.09 billion and debt to ~$955 million. We reiterate our Overweight rating and are increasing our price target to $110 from $100.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 13 at 7:52 AM
$SLS $BMY $RHHBY SLS009 news is due, Expected to coincide with the JPM Conference - this week. - and the fact is after the Holidays, we are now at 77/78 events, Thanksgiving, Christmas and New Years post holiday events. Smart money knows this, and that P3 results will be announced before we know it, and when they do, $47 will be cheap. - only inch thick mile wide retail lemming tools - with the forethought of Gold FISH don't have clue what it means to actually INVEST... and get in Early and CHEAP -- like right now. https://www.reddit.com/r/sellasLifescience/s/469bdHkImx
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:52 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:52 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
2 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint$LMDX
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:51 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jan. 13 at 3:50 AM
$LMDX $SPY $FCN $RHHBY $TAUNS $ELECTRADX $INVITA https://www.sec.gov/submit-tip-or-complaint
1 · Reply
MQuick
MQuick Jan. 12 at 5:49 PM
$GANX $RHHBY and $SNY its time
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 12 at 4:23 PM
$SLS $BMY $RHHBY Once this Cracks $4 - it puts $5 in Play Today -- it will happen - its Inevitable - SLS is going to be $40 per share and climbing - a Phase 3 Registrational Trial result IS coming and its worth Tens of billions. Since the holidays - we are now likely currently at 77/78 events, very close to 80 and everyone knows Gps Phase 3 results will absolutely launch this baby bio - plus we have an Imminent SLS009 PR, it will likely come this week with JPM CONFERENCE. shares are way oversold - hence all the lying short scumbags at work here and all over social media. From $5 and change to $145 Based on its P3 Results ... ABVX is a good example of what will be happening here.
0 · Reply
cielo1
cielo1 Jan. 12 at 1:24 PM
$IFRX $MLTX Small and mighty, lets see a merger with moonlake CEO at the helm! $MRK $RHHBY we can dream! Stellar value!
2 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 12 at 2:42 AM
$SLS Share price will be $40 + and Climbing SLS is worth Close to $180 per share to big pharma, all in warranted - it is inevitable Phase 3 results are coming. $BMY $RHHBY
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 12 at 12:45 AM
$SLS sad but true https://www.reddit.com/r/sellasLifescience/s/FNL0qBfFjX ​ ​$ABBV $BMY $RHHBY
0 · Reply
MQuick
MQuick Jan. 11 at 10:12 PM
$GANX $SNY $RHHBY you better make a move
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 11 at 10:44 AM
$SLS $ABBV $BMY $RHHBY
0 · Reply
MF__DOOM
MF__DOOM Jan. 9 at 10:43 PM
$QURE support needs to be retaken at $27 this was very predictable price action the good news is check my previous post date of 11/5/25 and you’ll see we have been consolidating for more than a month now right below $27 so it’s gonna be very shortly that we break above $30-40 RANGE and it will be quick when it breaks $80-100 is the target long term price (can come soon as eoy or 5 years out) and this price will easily come as well as for those who follow me or anybody here specifically with a history in Bio you’ll see every bio so far I’ve called out for a buyout has gotten it but also I say beware because a BO isn’t always good, as was the case with $BLUE, however I believe this will play out differently QURE already has a history with CSL Behring (not necessarily the bo buyer but CSL is my top guess followed by $BMY $PFE and $RHHBY last )
0 · Reply